ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage Therapeutics" or "the Company") (NASDAQ: SAGE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (i) zuranolone was less effective in treating major depressive disorder ("MDD") than Defendants had led investo ...